Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 101 - 125 of 224 in total
LY3039478 has been used in trials studying the treatment and basic science of LYMPHOMA, Neoplasms, Solid Tumor, COLON CANCER, and BREAST CANCER, among others.
Investigational
Matched Name: … LY-3039478 …
LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
Investigational
Matched Name: … LY-3023414 …
LY2608204 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
Investigational
Matched Name: … LY-2608204 …
LY2584702 has been used in trials studying the treatment of Cancer, Advanced Cancer, Renal Cell Carcinoma, Metastases, Neoplasm, and Neuroendocrine Tumors, among others.
Investigational
Matched Name: … LY-2584702 …
LY2334737 has been used in trials studying the treatment of Solid Tumor, Metastatic Tumor, and Malignant Solid Tumor.
Investigational
Matched Name: … LY-2334737 …
Ly2300559 has been used in trials studying the prevention of Migraine Headache.
Investigational
Matched Name: … LY-2300559 …
LY2811376 has been used in trials studying the basic science of Alzheimer's Disease.
Investigational
Matched Name: … LY-2811376 …
SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Investigational
Rusfertide is a hepcidin mimetic currently being developed by Protagonist Therapeutics for the treatment of polycythemia vera and beta-thalassemia.
Investigational
LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Investigational
Matched Name: … LY-517717 …
LY518674 has been used in trials studying the treatment of Metabolic Syndrome X.
Investigational
Matched Name: … LY-518674 …
Investigational
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
Investigational
Na 1 is under investigation in clinical trial NCT00728182 (Evaluating Neuroprotection in Aneurysm Coiling Therapy).
Investigational
LY2886721 has been used in trials studying the basic science of Alzheimer's Disease.
Investigational
Matched Name: … LY-2886721 …
LY2874455 has been used in trials studying the treatment of Advanced Cancer.
Investigational
Matched Name: … LY-2874455 …
LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).
Investigational
Matched Name: … LY-2881835 …
Matched Description: … LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People …
LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).
Investigational
Matched Name: … LY-3200882 …
Matched Description: … LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab …
LY-2183240 is an inhibitor of endocannabinoid reuptake/breakdown.
Investigational
Matched Name: … LY-2183240 …
Matched Description: … LY-2183240 is an inhibitor of endocannabinoid reuptake/breakdown.[A253037] …
Investigational
Seladelpar (MBX-8025) has been used in trials studying the treatment of Hyperlipidemia.
Investigational
Resolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).
Investigational
Experimental
Displaying drugs 101 - 125 of 224 in total